Journal of Oncology / 2012 / Article / Fig 1

Research Article

Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma

Figure 1

In vivo xenografts of human melanoma cancer cells treated with TekdeltaFc and LDM CTX. Relative tumor growth for each treatment group: Control, TekdeltaFc, low-dose metronomic cyclophosphamide (LDM CTX), and combination for two weeks. There were no statistically significant differences in tumor growth between treatment groups at any time points ( 𝑃 > 0 . 0 5 ).
794172.fig.001

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.